Literature DB >> 26497099

PML: The Dark Side of Immunotherapy in Multiple Sclerosis.

Clemens Warnke1, Tomas Olsson2, Hans-Peter Hartung3.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a threat to patients with multiple sclerosis (MS) who undergo treatment with drugs that interfere with normal immune physiology. Here, we summarize PML incidence in MS, risk factors, surveillance strategies, and case definitions to inform neurologists and other clinicians treating patients with immune-mediated diseases.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  JC virus; PML; natalizumab; risk

Mesh：

Substances：

Year:  2015        PMID： 26497099     DOI： 10.1016/j.tips.2015.09.006

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  10 in total

Review 1.  Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Authors:  Jens Ingwersen; Orhan Aktas; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 2.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 3.  Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Authors:  Joachim Havla; Clemens Warnke; Tobias Derfuss; Ludwig Kappos; Hans-Peter Hartung; Reinhard Hohlfeld
Journal:  Dtsch Arztebl Int       Date:  2016-12-26       Impact factor: 5.594

4.  Immune suppression of JC virus gene expression is mediated by SRSF1.

Authors:  Rahsan Sariyer; Francesca Isabella De-Simone; Jennifer Gordon; Ilker Kudret Sariyer
Journal:  J Neurovirol       Date:  2016-03-07       Impact factor: 2.643

5.  Injectable Disease Modifying Agents in Multiple Sclerosis: Pattern of Medication Use and Clinical Effectiveness.

Authors:  Elina Järvinen; Markus Holmberg; Marja-Liisa Sumelahti
Journal:  Neurol Int       Date:  2016-09-30

Review 6.  Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System.

Authors:  Deepti Pilli; Alicia Zou; Fiona Tea; Russell C Dale; Fabienne Brilot
Journal:  Front Immunol       Date:  2017-06-07       Impact factor: 7.561

7.  Severe Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression.

Authors:  Stephen P Persaud; Adil Hassan; Anjum Hassan; Tariq Hassan
Journal:  ACG Case Rep J       Date:  2017-03-15

8.  Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?

Authors:  Julia Krämer; Jan-Gerd Tenberge; Ingo Kleiter; Wolfgang Gaissmaier; Tobias Ruck; Christoph Heesen; Sven G Meuth
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

9.  Self-Limited Cytomegalovirus Infection During Natalizumab Treatment for Multiple Sclerosis.

Authors:  Marina Rodrigues Lima; Luís Arthur Brasil Gadelha Farias; Maycon Fellipe da Ponte; Luís Edmundo Teixeira de Arruda Furtado
Journal:  Eur J Case Rep Intern Med       Date:  2019-02-01

10.  Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.

Authors:  Kathleen Ingenhoven; Daniel Kramer; Poul Erik Jensen; Christina Hermanrud; Malin Ryner; Florian Deisenhammer; Marc Pallardy; Til Menge; Hans-Peter Hartung; Bernd C Kieseier; Elisa Bertotti; Paul Creeke; Anna Fogdell-Hahn; Clemens Warnke
Journal:  Front Neurol       Date:  2017-07-06       Impact factor: 4.003
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.